Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine TrialMartin Kaiser, Matthew Jenner, Sadie Roberts et al.|Blood|2022Cited by 10
Incorporating Molecular Data Into Treatment Decision Making in Gastroesophageal and Pancreaticobiliary Cancers: Timing and StrategiesAndrew Hall, Andrew B. Nixon, Sarah Brown et al.|American Society of Clinical Oncology Educational Book|2024Cited by 3